Streetbeat News

Price Targets

BBIO

Citi has initiated coverage on BridgeBio Pharma Inc (BBIO) with an optimistic outlook, citing the substantial market potential of acoramidis, especially after its recent Phase 3 successes in treating ATTR cardiomyopathy. Citi recommends a Buy/High Risk with a price target of $42. The analysts also anticipate that acoramidis could achieve blockbuster sales levels post its expected launch in H2 2024. Other promising candidates in BBIO's pipeline include infigratinib, encaleret, and BBP-418.

Portfolio Pulse from Vandana Singh

November 07, 2023 | 9:28 pm

CMT

EF Hutton analyst Chip Moore maintains a 'Buy' rating on Core Molding Technologies (AMEX:CMT) but has lowered the price target from $28 to $25.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 8:36 pm

STOK

Needham analyst Joseph Stringer has maintained a 'Buy' rating on Stoke Therapeutics (NASDAQ:STOK) but lowered the price target from $25 to $14.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 8:32 pm

ESPR

Needham analyst Serge Belanger has maintained a 'Buy' rating on Esperion Therapeutics (NASDAQ:ESPR) but lowered the price target from $9 to $8.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 8:29 pm

COHR

Needham analyst James Ricchiuti has maintained a 'Buy' rating on Coherent (NYSE:COHR) but lowered the price target from $50 to $46.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 8:25 pm

RVMD

JP Morgan analyst Eric Joseph has maintained an Overweight rating on Revolution Medicines (NASDAQ:RVMD) but lowered the price target from $47 to $39.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 8:23 pm

PRME

JP Morgan analyst Eric Joseph has maintained an Overweight rating on Prime Medicine (NASDAQ:PRME) but lowered the price target from $27 to $26.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 8:21 pm

OPRT

JP Morgan analyst Richard Shane has maintained a Neutral rating on Oportun Financial (NASDAQ:OPRT) and lowered the price target from $8 to $6.5.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 8:20 pm

MYGN

JP Morgan analyst Rachel Vatnsdal has maintained an Underweight rating on Myriad Genetics (NASDAQ:MYGN) and lowered the price target from $17 to $14.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 8:15 pm

HLLY

JP Morgan analyst Christian Carlino has maintained an Overweight rating on Holley (NYSE:HLLY) but lowered the price target from $9 to $7.5.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 8:13 pm